Trial Profile
A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 18 Jul 2018 Status changed from active, no longer recruiting to completed.
- 30 Jun 2018 The trial has been completed in Germany. (End date: 2018-03-16)
- 29 Jun 2018 The trial has been completed in Sweden. (End date: 2018-03-16)